Participated · Series B · Aug 2026

Inocras develops whole-genome sequencing and proprietary bioinformatics solutions to translate comprehensive genomic data into curated, clinically actionable insights. Its oncology offerings include CancerVision™ for comprehensive tumor profiling and MRDVision™ for molecular residual disease detection, with automated interpretation capabilities. The company operates a CLIA/CAP-certified laboratory and reports real-world clinical adoption across Asia, with its solutions used by more than 100 cancer institutions and in thousands of patient cases. Inocras has established a significant commercial presence in Hong Kong and supports approximately thirty hospitals in South Korea. The company has collaborated with researchers at the Broad Institute to analyze whole-genome data from The Cancer Genome Atlas, informing broader use of standardized whole-genome analysis. The recent fundraise brought total funding to approximately $100 million to support further commercial expansion, particularly into the United States.

Participated · Series A · Jul 2026

CarbonSix develops deployment-ready robotic intelligence software and hardware, including robotic hands and manipulators, for manufacturing applications. The company emphasizes field reliability and immediate integration into production lines, and reports commercial contracts and scaling revenue as evidence of market traction. Its core business model is a proprietary "data flywheel" where tool usage in factories generates task-specific data that improves its AI models over time. The founding team includes executives and researchers with prior exits and advanced academic credentials, supporting technical and commercial credibility. CarbonSix plans to use its Series A proceeds to hire talent, scale infrastructure, and expand into global markets.

Participated · Seed · May 2026

Asteromorph develops a foundation model, Spacer, that it says combines a base LLM with deep domain knowledge and multi-step reasoning to autonomously generate research ideas and scientific hypotheses in biology and chemistry. Its flagship initiative, the "Library Project," aims to run the autonomous system at scale to uncover fundamental mechanisms of life and compile findings into a structured database. The company emphasizes autonomous hypothesis generation and end-to-end scientific workflows rather than solely assisting human researchers. Leadership includes CEO Lee Min-hyung, who entered advanced research training early, and a core team of young researchers from top Korean STEM programs. Financially, Asteromorph has raised a $31.4M seed round and previously raised approximately ₩5 billion. The company faces the challenge of validating model-generated discoveries through rigorous experimental work at scale.

Participated · Series E · Apr 2026

Brave group is an IP production company centered on VTuber talent and related businesses, operating projects including ぶいすぽっ！, HIMEHINA, and Neo-Porte. The company has pursued international expansion into English-speaking markets, Korea, and China. Founded in October 2017, Brave group has raised cumulative funding of about ¥14 billion to date. Its business spans talent management, streaming activities, music production, live events, and merchandise production as part of broader IP commercialization. Following the Series E financing, GREE Holdings (via REALITY) became the company's largest shareholder, strengthening a strategic partnership. Brave group plans to use new proceeds to accelerate global expansion, diversify IP businesses, invest in technology, and pursue strategic M&A.

Participated · Series C · Apr 2026

Mediwhale develops AI-driven retinal imaging analysis tools that predict cardiovascular risk from a single eye image, marketed under names including Dr. Noon CVD. The company is focused on commercializing those AI biomarkers and expanding partnerships with imaging hardware vendors such as iCare. Mediwhale is actively pursuing FDA De Novo clearance to access the U.S. market and has publicly stated plans to prepare for a public listing, targeting KOSDAQ in 2027 while positioning for a broader U.S. listing narrative. Financially, the firm has raised roughly ₩51.2 billion (about $34M) to date, most recently securing ₩20 billion in a Series C. The company emphasizes scaling global commercialization and regulatory readiness as near-term priorities.